Petach Tikva, Israel — September 3, 2025 — Leads & Copy — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company focused on improving surgical outcomes, will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8-9, 2025, at the Lotte New York Palace Hotel in New York City.
PolyPid’s fireside chat with H.C. Wainwright Managing Director, Equity Research, Brandon Folkes, will take place from 11:30 AM – 12:00 PM ET on Monday, September 8, 2025. The PolyPid management team will also participate in virtual and in-person one-on-one investor meetings during the event. Investors can request a one-on-one meeting with PolyPid through their H.C. Wainwright representative or by e-mailing meetings@hcwco.com.
PolyPid Ltd. (Nasdaq: PYPD) aims to improve surgical outcomes through locally administered, controlled, prolonged-release therapeutics. Its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise drug delivery at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, a New Drug Application (NDA) submission of D-PLEX₁₀₀, PolyPid’s lead product candidate for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. The Company also has an innovative pipeline in oncology, obesity, and diabetes.
Contact: Ori Warshavsky, 908-858-5995, IR@Polypid.com; Arx | Capital Markets, North American Equities Desk, polypid@arxadvisory.com
Source: PolyPid Ltd.
